Dolutegravir
=============

**PD Dialyzability**: Unlikely

Pharmacokinetic Parameters [1]_ [2]_
------------------------------------------

======= ======
/////// |pk|
======= ======
|pk1|   |v1|
|pk2|   |v2|
|pk3|   |v3|
|pk4|   |v4|
|pk5|   |v5|
|pk6|   |v6|
|pk7|   |v7|
======= ====== 

CAPD/CCPD Dosing: 
------------------
No dosing recommendation for PD population was found in literature. However, due to extensive protein binding and minimal renal clearance of unchanged drugs, it is unlikely that dosing adjustment is required [1]_.

Literature Summary:
---------------------------

None identified.  


References
------------

.. [1] Chan A, Tseng A. Selected properties of dolutegravir. Immunodeficiency Clinic [Internet]. 2014 Dec [cited 2018 Jan 17]. 1-6. Available from www.hivclinic.ca.

.. [2] Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-672.

.. |pk| replace:: Dolutegravir
.. |pk1| replace:: Molecular Weight (Da)  
.. |pk2| replace:: Plasma Protein Binding (%)
.. |pk3| replace:: Volume of Distribution (L/Kg) 
.. |pk4| replace:: Hepatic Metabolism 
.. |pk5| replace:: Excreted Unchanged (%) 
.. |pk6| replace:: Half-Life; Normal Renal Function (hours)
.. |pk7| replace:: Half-Life; ESRD (hours) 
.. |v1| replace:: 419
.. |v2| replace:: > or equal to 98.9
.. |v3| replace:: 17.4 L
.. |v4| replace:: UGT1A1, some CYP3A
.. |v5| replace:: < 1
.. |v6| replace:: 14
.. |v7| replace:: Unknown